CoChat

Advanced Glycation End Product Precursors Impair Epidermal Growth Factor Receptor Signaling

Portero-Otín, Manuel, Pamplona, Reinald, Bellmunt, Maria Josep, Ruiz, Maria Cristina, Prat, Joan, Salvayre, Robert, Nègre-Salvayre, Anne · 2002 · Diabetes
Cited by 92

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Formation of advanced glycation end products (AGEs) is considered a potential link between hyperglycemia and chronic diabetic complications, including disturbances in cell signaling. It was hypothesized that AGEs alter cell signaling by interfering with growth factor receptors. Therefore, we studied the effects of two AGE precursors, glyoxal (GO) and methylglyoxal (MGO), on the epidermal growth factor receptor (EGFR) signaling pathway in cultured cells. Both compounds prevented tyrosine autophosphorylation induced by epidermal growth factor (EGF) in a time- and dose-dependent manner as well as phospholipase Cγ1 recruitment and subsequent activation of extracellular signal-regulated kinases. AGE precursors inhibit EGF-induced EGFR autophosphorylation and tyrosine kinase activity in cell membranes and in EGFR immunoprecipitates. In addition, AGE precursors strongly inhibited cellular phosphotyrosine phosphatase activities and residual EGFR dephosphorylation. AGE precursors induced the formation of EGFR cross-links, as shown by the cross-reactivity of modified EGFR with an anti-Nε(carboxymethyl)lysine antibody, suggesting that altered EGFR signaling was related to carbonyl-amine reactions on EGFR. Aminoguanidine, an inhibitor of AGE formation, partially prevented the EGFR dysfunction induced by GO and MGO. These data introduce a novel mechanism for impaired cellular homeostasis in situations that lead to increased production of these reactive aldehydes, such as diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/diabetes.51.5.1535

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 92

Metadata

Authors
Portero-Otín, M., Pamplona, R., Bellmunt, M. J., Ruiz, M. C., Prat, J., Salvayre, R., & Nègre-Salvayre, A.
Venue
Diabetes
Published
2002-05-01
Volume
51
Issue
5
Pages
1535-1542
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2038436979
Cited by
92
References
3
FWCI
4.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Advanced Glycation End Product Precursors Impair Epidermal Growth Factor Receptor Signaling. https://app.cochat.ai/papers/10.2337/diabetes.51.5.1535
The paper
Portero-Otín, M., Pamplona, R., Bellmunt, M. J., Ruiz, M. C., Prat, J., Salvayre, R., & Nègre-Salvayre, A. (2002). Advanced Glycation End Product Precursors Impair Epidermal Growth Factor Receptor Signaling. Diabetes. https://doi.org/10.2337/diabetes.51.5.1535

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.